Zevra Therapeutics, Inc. (ZVRA)
After hours:
| Previous close | 4.6500 |
| Open | 4.6700 |
| Bid | 4.8000 x 100 |
| Ask | 4.8300 x 200 |
| Day's range | 4.5901 - 4.8600 |
| 52-week range | 3.8900 - 7.2800 |
| Volume | |
| Avg. volume | 205,403 |
| Market cap | 201.315M |
| Beta (5Y monthly) | 1.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3200 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.00 |
GlobeNewswireZevra Therapeutics Expands Executive Leadership Team
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertis
Simply Wall St.Breakeven On The Horizon For Zevra Therapeutics, Inc. (NASDAQ:ZVRA)
We feel now is a pretty good time to analyse Zevra Therapeutics, Inc.'s ( NASDAQ:ZVRA ) business as it appears the...
- GlobeNewswire
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA® is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders (UCDs) involving deficienc
